Evidence map›Paper›PMID 36469217›Full record

ArticleScience China. Life sciences2023

New insight into immune checkpoint inhibitors in the treatment of advanced renal cell carcinoma.

Hu Wang, Zhiqiang Zhu, Yihang Zhang, Taiyi Jiang, Mengmeng Zhang, Zongping Wang, Yu Zhang, An Zhao, Bin Su

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05705583 (A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05705583 unknown statusnot on this map

A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma

TypeobservationalSponsorZhejiang Cancer HospitalRan2023 to 2025Enrolled100ConditionsRenal Cell CarcinomaArmsOther: Blood and Urine Collection
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hu Wang *Beijing Key Laboratory for HIV/AIDS Research, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Zhiqiang Zhu *Department of Urology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Yihang Zhang *Beijing Key Laboratory for HIV/AIDS Research, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Taiyi JiangBeijing Key Laboratory for HIV/AIDS Research, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Mengmeng ZhangDepartment of Urology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Zongping WangDepartment of Urology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China.
Yu ZhangDepartment of Urology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. zhangyud@ccmu.edu.cn.
An ZhaoExperimental Research Center, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, 310022, China. zhaoan@zjcc.org.cn.
Bin SuBeijing Key Laboratory for HIV/AIDS Research, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. binsu@ccmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyMolecular Targeted TherapyImmune Checkpoint Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.